Деякі лікарські засоби цільової терапії недрібноклітинного раку легенів
Target | Drug | NSCLC |
|---|---|---|
ALK rearrangement | Alectinib Brigatinib Ceritinib Crizotinib | Adenocarcinoma |
BRAF mutation | Dabrafenib Trametinib | Adenocarcinoma Squamous cell carcinoma |
EGFR mutation | Afatinib Erlotinib Gefitinib Necitumumab | Adenocarcinoma Squamous cell carcinoma |
EGFR (T790M mutation) | Osimertinib | Adenocarcinoma |
Inhibit blood vessel growth | Bevacizumab Ramucirumab | Adenocarcinoma |
Immune activation (checkpoint inhibitors) | Atezolizumab Cemiplimab Durvalumab Ipilimumab Nivolumab Pembrolizumab | Adenocarcinoma Squamous cell carcinoma |
NSCLC = Non–small cell lung cancer. | ||
Серед цих тем